Online inquiry

IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10028MR)

This product GTTS-WQ10028MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FN gene. The antibody can be applied in Lymphoproliferative disease research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001306129.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2335
UniProt ID P02751
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10028MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ566MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ4907MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ6947MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ6722MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ6423MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ13058MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ6828MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW